Clinical Scorecard: FDA approves once-weekly insulin for type 2 diabetes

At a Glance

Key Highlights

• Insulin efsitora alfa-gobe approved as adjunct to diet and exercise
• Met primary endpoint of noninferiority for hemoglobin A1c reduction
• Safety findings comparable to once-daily insulin comparators
• Common adverse reactions include hypoglycemia and allergic reactions
• Not for use in patients with type 1 diabetes due to severe hypoglycemia risk

Guideline-Based Recommendations

Diagnosis

Management

• Administer subcutaneously once weekly on the same day each week

Monitoring & Follow-up

Risks

• Increased risk of severe hypoglycemia in type 1 diabetes
• Concomitant use of thiazolidinediones may worsen heart failure

Patient & Prescribing Data

Adults with type 2 diabetes, both insulin-naive and those previously treated with basal insulin

Available in concentrations of 500 units/mL and 1,000 units/mL

Clinical Best Practices

• Monitor for common adverse reactions such as hypoglycemia and injection-site reactions
• Educate patients on the importance of adherence to weekly dosing schedule

Related Resources & Content

• Eli Lilly and Company Press Release